US court confirms protection for Pfizer's Lyrica until 2018, hitting ANDA challenges
This article was originally published in Scrip
Pfizer secured patent protection through to the end of 2018 for Lyrica (pregabalin) on 19 July when a US federal court judge said that the patents licensed from Northwestern University were valid and infringed by Teva Pharmaceuticals' and other manufacturers' US abbreviated new drug applications (ANDAs) for a generic formulation of the blockbuster pain drug.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.